Adipogen/Podophyllotoxin/AG-CN2-0049-M100/100 mg
More Information
Product Details
Synonyms Podofilox; NSC 24818; Podophyllinic acid lactone
Product Type Chemical
Properties
Formula C22H22O8
MW 414.4
Merck Index 14: 7546
CAS 518-28-5
RTECS LZ2500000
Source/Host Chemicals Isolated from Podophyllum emodi rhizomes.
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Soluble in chloroform, acEtone, ethyl acetate or ethanol. Insoluble in water.
InChi Key YJGVMLPVUAXIQN-LBXUKJEYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Hygroscopic.
Keep under inert gas.
Protect from moisture.
Use/Stability StABLe for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent microtubule assembly inhibitor [1-3].
  • Anticancer compound [1-5, 7].
  • Cell death inducer [1-5, 7].
  • DNA topoisomerase II inhibitor. Cell cycle inhibitor at the metaphase [2, 6, 8].
  • Antiviral [3, 4, 9] and antihelminthic [1].
Product References
  1. VP16-213 and Podophyllotoxin. A study on the relationship between chemical structure and biological activity: J.D. Loike; Cancer Chemother. Pharmacol. 7, 103 (1982)
  2. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents: T. Terada, et al.; Chem. Pharmacol. Bull. (Tokyo) 40, 2720 (1992)
  3. Antineoplastic and antiviral activities of podophyllotoxin related lignans: M. Gordaliza, et al.; Arch. Pharmacol. 327, 175 (1994)
  4. Podophyllotoxin: C. Canel, et al.; Phytochemistry 54, 115 (2000) (Review)
  5. Antitumor properties of podophyllotoxin and related compounds:  M. Gordaliza, et al.; Curr. Pharm. Des. 6, 1811 (2000) (Review)
  6. Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues: S. Desbene & S. Giorgi-Renault; Curr. Med. Chem. Anticancer Agents 2, 71 (2002) (Review)
  7. Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents: Y. You; Curr. Pharm. Des. 11, 1695 (2005) (Review)
  8. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile: J.T. Hartmann & H.P. Lipp; Drug Saf. 29, 209 (2006) (Review)
  9. An evidence-based review of medical and surgical treatments of genital warts: N. Scheinfeld & D.S. Lehman; Dermatol. Online J. 12, 5 (2006)